1h Free Analyst Time
The amyotrophic lateral sclerosis treatment market is forecasted to grow by USD 207.5 million during 2024-2029, accelerating at a CAGR of 4.8% during the forecast period. The report on the amyotrophic lateral sclerosis treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in incidence and prevalence of amyotrophic lateral sclerosis, huge unmet need for amyotrophic lateral sclerosis, and high research funding on amyotrophic lateral sclerosis treatment.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The amyotrophic lateral sclerosis treatment market is segmented as below:
By Type
- Intravenous
- Oral
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Drug Class
- Riluzole
- Symptomatic treatments
- Edaravone
- Muscle relaxants
- Antisense oligonucleotides
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the amyotrophic lateral sclerosis treatment market covers the following areas:
- Amyotrophic Lateral Sclerosis Treatment Market sizing
- Amyotrophic Lateral Sclerosis Treatment Market forecast
- Amyotrophic Lateral Sclerosis Treatment Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Distribution Channel
10 Market Segmentation by Drug Class
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global amyotrophic lateral sclerosis treatment market: AB Science SA, Alkem Laboratories Ltd., Apotex Inc., Aquestive Therapeutics Inc, Biogen Inc., Brainstorm Cell Therapeutics Inc., CORESTEM Inc., Denali Therapeutics Inc., DR Reddys Laboratories Ltd., Eledon Pharmaceuticals, Ionis Pharmaceuticals Inc., Italfarmaco Holding SPA, Medindia Health, Mitsubishi Chemical Group Corp., Otsuka Holdings Co. Ltd., Revalesio Corp., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Treeway BV.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increase in aging population."
According to the report, one of the major drivers for this market is the increase in incidence and prevalence of amyotrophic lateral sclerosis.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- Alkem Laboratories Ltd.
- Apotex Inc.
- Aquestive Therapeutics Inc
- Biogen Inc.
- Brainstorm Cell Therapeutics Inc.
- CORESTEM Inc.
- Denali Therapeutics Inc.
- Dr Reddys Laboratories Ltd.
- Eledon Pharmaceuticals
- Ionis Pharmaceuticals Inc.
- Italfarmaco Holding SPA
- Medindia Health
- Mitsubishi Chemical Group Corp.
- Otsuka Holdings Co. Ltd.
- Revalesio Corp.
- Sanofi SA
- Sun Pharmaceutical Industries Ltd.
- Treeway BV
